Determination of cefalothin and cefazolin in human plasma, urine and peritoneal dialysate by UHPLC-MS/MS: application to a pilot pharmacokinetic study in humans

Parker, Suzanne L., Guerra Valero, Yarmarly C., Roberts, Darren M., Lipman, Jeffrey, Roberts, Jason A. and Wallis, Steven C. (2016) Determination of cefalothin and cefazolin in human plasma, urine and peritoneal dialysate by UHPLC-MS/MS: application to a pilot pharmacokinetic study in humans. Biomedical Chromatography, 30 6: 872-879. doi:10.1002/bmc.3622


Author Parker, Suzanne L.
Guerra Valero, Yarmarly C.
Roberts, Darren M.
Lipman, Jeffrey
Roberts, Jason A.
Wallis, Steven C.
Title Determination of cefalothin and cefazolin in human plasma, urine and peritoneal dialysate by UHPLC-MS/MS: application to a pilot pharmacokinetic study in humans
Journal name Biomedical Chromatography   Check publisher's open access policy
ISSN 1099-0801
Publication date 2016-06-01
Year available 2016
Sub-type Article (original research)
DOI 10.1002/bmc.3622
Open Access Status Not Open Access
Volume 30
Issue 6
Start page 872
End page 879
Total pages 8
Place of publication Chichester, West Sussex United Kingdom
Publisher John Wiley & Sons
Collection year 2017
Language eng
Abstract An ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) method for the analysis of cefazolin and cefalothin in human plasma (total and unbound), urine and peritoneal dialysate has been developed and validated. Total plasma concentrations are measured following protein precipitation and are suitable for the concentration range of 1–500 µg/mL. Unbound concentrations are measured from ultra-filtered plasma acquired using Centrifree® devices and are suitable for the concentration range of 0.1–500 µg/mL for cefazolin and 1–500 µg/mL for cefalothin. The urine method is suitable for a concentration range of 0.1–20 mg/mL for cefazolin and 0.2–20 mg/mL for cefalothin. Peritoneal dialysate concentrations are measured using direct injection, and are suitable for the concentration range of 0.2–100 µg/mL for both cefazolin and cefalothin. The cefazolin and cefalothin plasma (total and unbound), urine and peritoneal dialysate results are reported for recovery, inter-assay precision and accuracy, and the lower limit of quantification, linearity, stability and matrix effects, with all results meeting acceptance criteria. The method was used successfully in a pilot pharmacokinetic study with patients with peritoneal dialysis-associated peritonitis, receiving either intraperitoneal cefazolin or cefalothin.
Keyword b-lactam antibiotics
UHPLC-MS/MS
Bio-analysis
Protein binding
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Admin Only - School of Medicine
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 17 May 2016, 00:22:32 EST by System User on behalf of School of Medicine